Data science uncovers drug interactions with significant risks

Warnings for specific prescription drugs may not cover the implications of mixing certain medications, which can mean side effects much worse than just dizziness or upset stomach. While many of the dangerous drug parings have been discovered, many are still hidden. Researchers from New York's Columbia University Medical Center and the Data Science Institute at Columbia University are using data science to uncover such interactions.

Researchers were able to use a government database of reported drug side effects and match them with patient records to discover eight pairs of potential dangerous drugs that lead to a higher rate of deadly heart conditions. The combined medications deemed the most dangerous consisted of ceftriaxone and lansoprazole, a heartburn medication more commonly known as Prevacid.

Alone, the medications do not lead to heart-related risks. But together, they were found to affect the electoral activity in the heart. Together, they can lead to the development of long QT syndrome, when the heart rhythm is effected and may cause sudden death, and are 1.4 times more likely to have an extended QT interval.

"What's most surprising is that you can go from a database of billions of data points to making a prediction that two molecules together can change the functions of a protein in a single heart cell," said Nicholas Tatonetti, PhD, assistant professor of biomedical informatics at Columbia University Medical Center and a member of Columbia's Data Science Institute. "It means these algorithms are really useful in medical research."

The U.S. Food and Drug Administration has been informed of these findings in the hope that further testing on combining ceftriaxone lansoprazole with three other potentially dangerous medications.

"Drug interactions occur often, but they often go unrecognized, and we have needed better methods of detection," said Raymond Woosley, MD, PhD, a national expert on drug-induced long QT syndrome and founding president of ACZERT, an Arizona nonprofit organization focused on drug safety. 

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.